Navigation Links
Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab
Date:8/3/2009

at include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2009, filed with the SEC on May 11, 2009, as well as other filings by the company with the SEC.


'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet Announces Pricing of Public Offering of Common Stock
2. Micromet Announces Public Offering of Common Stock
3. Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009
4. Micromet Added to Russell 3000 Index
5. Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
6. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
7. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
8. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
9. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
10. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
11. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014 July 30, 2014. ... a biotechnology firm that provides DNA-based authentication and security ... Ph.D. Vice President of Life Sciences, a newly created ... , Dr. Hogan will lead APDN’s drive to build ... with biotech and healthcare customers, provide guidance to APDN’s ...
(Date:7/30/2014)... , July 30, 2014  Dyadic International, Inc. ... whose patented and proprietary technologies are used to ... proteins for the bioenergy, bio-based chemical, biopharmaceutical and ... Thomas "Tom" Dubinski as Vice President and Chief ... the financial and information technology operations for Dyadic ...
(Date:7/30/2014)... Edwardsville, IL (PRWEB) July 30, 2014 ... Dr. Arun Athmanathan will present his findings on ... of Energy conference this week in Washington, D.C. ... Department of Energy conference is a testament to ... Director John Caupert said. “Thanks to the foresight ...
(Date:7/30/2014)... 30, 2014 LayerBio, Inc., an MIT ... its first round of seed financing from friends and ... efforts to develop a novel sustained-release product for ophthalmology. ... investors and their commitment to this important work," said ... is one of many areas in which innovations in ...
Breaking Biology Technology:Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3
... , VANCOUVER , July 28 ... ANP) ("Angiotech") and partner Athersys, Inc. (NASDAQ: ATHX) ... trial of MultiStem(R), its allogeneic cell therapy product, ... more commonly referred to as a heart attack. ...
... July 28 VIASPACE Inc. (OTC Bulletin Board: ... a low-carbon, renewable biomass crop, reported that Chief Executive Dr. ... Third Annual World Congress of Industrial Biotechnology held in ... than 500 business executives, industry leaders, technical experts, government officials ...
... July 27 ITelagen, a leading provider of electronic health record ... Asthma Associates of Northern California , San Jose, CA ... includes hosting of patient data in ITelagen,s SAS-70 Type II certified datacenter ... , , ...
Cached Biology Technology:Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 2Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 3Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 4Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 5Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 6Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 7Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 8Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 9VIASPACE CEO Discusses Giant King Grass at Industrial Biotechnology Congress in China 2VIASPACE CEO Discusses Giant King Grass at Industrial Biotechnology Congress in China 3VIASPACE CEO Discusses Giant King Grass at Industrial Biotechnology Congress in China 4Allergy and Asthma Associates Selects ITelagen for Hosting and Management of EHR 2Allergy and Asthma Associates Selects ITelagen for Hosting and Management of EHR 3
(Date:7/30/2014)... Everybody knows the shortest distance between two points is ... that sperm have been taking the familiar axiom to ... usually thought to be intense, with each racing for ... in some species, sperm form cooperative groups that allow ... , A new study, conducted by Heidi Fisher, ...
(Date:7/30/2014)... Sciences Institute (SALSI), a joint venture between The University ... of Texas Health Science Center at San Antonio, has ... The winners, Emily Boice from UTSA and Lei Huang ... their project titled, "Novel engineered ferritins for tracking and ... and Huang,s research is focused on finding a treatment ...
(Date:7/30/2014)... Laboratory has received a pledge of $1 million from ... the Laboratory,s new Neurobehavioral Biometry Center. , ... will enable the Laboratory to develop a greater breadth ... ultimate goal of accelerating the pace of research to ... as a premier resource for the Laboratory and its ...
Breaking Biology News(10 mins):When cooperation counts 2When cooperation counts 3Rossi Foundation pledges $1M for JAX neurobehavioral research center 2
... Hopkins researchers say they have discovered a cause-and-effect ... schizophrenia previously believed to be independent of one ... to develop better drugs to treat the cognitive ... illnesses. ,Researchers have long studied the role ...
... 2012 The University of Miami (UM) Rosenstiel School of ... 2012-2013 Alumni Awards. The grantees were selected by a ... more than $11,000 in funds. , "We received 30 applications ... biology to meteorology," said Laura Bracken Chaibongsai, Alumni & Outreach ...
... place certain types of living cells on a microscope slide, ... and assemble themselves into a simple, if primitive tissue. A ... and then some, about the mechanical structure and behavior of ... Proceedings of the National Academy of Sciences , chemical ...
Cached Biology News:Johns Hopkins researchers link 2 biological risk factors for schizophrenia 2Recipients of UM Rosenstiel School's 2012-2013 Alumni Awards announced 2Force of nature: Defining the mechanical mechanisms in living cells 2Force of nature: Defining the mechanical mechanisms in living cells 3Force of nature: Defining the mechanical mechanisms in living cells 4
... Silver Staining Kit, 1. Select from ... and peptides on denaturing, native, and ... reproducibility with precast gels, buffer strips, ... to that of radioisotopes with ready-to-use ...
Human HAPLN1 MAb (Clone 316119) Protein Family: Hyaluronan (HA) & HA Binding Proteins, Proteoglycan Regulators...
... Anti-Major DNA-binding protein(DBP). Protein ... NP_001343 ELISA titre using ... Suggested conditions for Western Blot: ... buffer, and HRP conjugated anti-Rabbit IgG should ...
... GI Number: 4503277 Accession Number: ... FUNCTION: Supplies the nucleotide substrate for ... H 2 O = dUMP + ... Belongs to the Diseases: Benign Tumor; ...
Biology Products: